Juan C. Jaen

RCUS President Juan C. Jaen sells 31,431 shares for $877,501.25 via pre-arranged 10b5-1 plan; stock up 35.8% in 90 days.

Juan C. Jaen, President of Arcus Biosciences, executed 4 separate sales totaling 31,431 shares for $877,501.25 across June 22–24, 2026, reducing his holdings by 3.4%. The filing discloses this transaction is part of a pre-arranged 10b5-1 trading plan adopted on 2026-02-27, making it scheduled rather than discretionary. RCUS stock has appreciated 35.8% over the prior 90 days and currently trades at $28.80, near its 52-week high of $29.85. Against this backdrop, Jaen's prior trades at RCUS show mixed results: 5 prior sales returned -9.5%, -6.0%, -1.6%, -5.7%, and +11.3% over 30 days, with inconsistent longer-term performance. The company generated $17.0M in quarterly revenue but reported negative net income of -$128.0M and annual revenue declined 4.3% year-over-year, indicating operational challenges despite recent stock appreciation. The scheduled nature of the plan constrains interpretation of timing, but the combination of significant recent stock gains and underlying negative profitability merits investor attention.

RCUS President sells 31.8K shares ($681.3K) across 3 transactions at blended $21.41; holds 922.2K post-sale in unprofitable biotech company.

Jaen Juan C., President of Arcus Biosciences, executed 3 separate sales totaling 31,823 shares for $681,341.82 on 2026-01-05 at an average price of $21.41, reducing holdings by 3.3% to 922,240 shares. The stock currently trades at $23.20, placing the transaction prices 7.7% below current market levels. Arcus is a deeply unprofitable biotech company with -$135,000,000.00 net income on $26,000,000.00 quarterly revenue, operating at a substantial loss while exhibiting strong top-line growth of 120.5% year-over-year. The 90-day price performance context is mixed: the stock has risen 53.0% over 90 days but fallen 10.1% over the last 30 days, creating a volatile environment near its 52-week high of $26.10. Across his same-ticker history at RCUS, the President has executed 5 prior sales, none of which have yet generated measurable 90-day outcomes, leaving the pattern of timing at this specific ticker unresolved.

President Jaen Juan C. sold 82,997 shares of RCUS at $24.71; holding drops to 954,063 shares post-sale.

Jaen Juan C., President of Arcus Biosciences, executed an open-market sale of 82,997 shares (83.0K shares) on 2025-12-04 at $24.71, reducing his holdings by 8.0% to 954.1K shares. The sale occurred near the stock's 52-week high of $26.10 (-2.5%), following a robust 30-day gain of +28.9% and 90-day advance of +108.8%. Arcus reported a quarterly revenue of $26.0M but remains unprofitable with a $-135.0M net loss; however, the company has achieved +120.5% annual revenue growth. Across his cross-ticker track record, the insider's 9 prior sells show a 100.00% well-timed rate at the 90-day mark, though at RCUS specifically, his 5 prior trades show no measurable 90-day outcomes yet and mixed 30-day results. The timing proximity to the 52-week high and the strength of recent price momentum provide context for this discretionary reduction in equity exposure.

President Juan C. Jaen sold 50,000 shares at $20.26 avg ($1.0M) on Nov 17–18; RCUS stock near 52-week high, up 92.9% in 90 days.

Jaen executed 3 separate sales totaling 50,000 shares for $1,012,764.29 over two trading days as RCUS approached its 52-week high of $20.35, now trading at $20.22. The stock has rallied 92.9% over 90 days and 15.7% over 30 days, creating a window at elevated valuations. Despite strong recent price action, the company remains unprofitable (net income of $-135,000,000.00 in the latest full fiscal year) while generating $26,000,000.00 in quarterly revenue. Jaen's cross-ticker track record shows a 100.00% well-timed rate across 6 prior sells, though his measurable prior transactions at RCUS (5 trades, most from October 2025 with outcomes not yet measurable) offer limited timing precedent at this specific ticker.

President Jaen Juan C. sold 96.9K shares ($2.0M) at $20.76 avg; stock +48.5% in 30d, +120.4% in 90d from lows

Jaen Juan C., President of Arcus Biosciences, executed 4 separate sales totaling 96,859 shares for $2,010,578.37 on 2025-10-28 and 2025-10-29, reducing his holdings by 8.2%. The stock is trading near its 52-week high ($20.29) with strong recent momentum (+48.5% over 30 days, +120.4% over 90 days from the $6.87 low). Notably, his prior two sales at RCUS in February 2024 both proved well-timed at the 90-day mark (30d returns of -6.1% and -9.2%, 90d returns of -19.8% and -19.6%), and his cross-ticker track record shows a 100% well-timed rate on sells. However, the company remains unprofitable with a $-135.0M net loss on $26.0M quarterly revenue, despite 120.5% annual revenue growth. The timing of this sale—at near-peak valuations and amid ongoing losses—warrants attention to whether it reflects conviction about near-term valuation levels or capital allocation decisions by senior management.